<p><strong>紐約，紐約 / ACCESS Newswire /2025 年 8 月 4 日/</strong> 如果您在 <strong>Replimune Group, Inc.</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
<p>https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5</p>
<p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
<p><strong>訴訟：</strong> 針對 Replimune Group, Inc.提起了一項集體訴訟，旨在為在 2024 年 11 月 22 日至 2025 年 7 月 21 日期間受到證券欺詐影響的股東追回損失。</p>
<p><strong>案件詳情：</strong> 提起的投訴指控被告作出了虛假陳述和/或隱瞞了以下事實：(1) 被告在知道或應該知道的重大問題下，魯莽地誇大了 IGNYTE 試驗的前景，導致 FDA 認為 IGNYTE 試驗不充分且控制不佳；(2) 因此，被告關於 Replimune 的業務、運營和前景的陳述在所有相關時間內都是實質性虛假和誤導的，或完全缺乏合理依據。</p>
<p><strong>接下來會發生什麼？</strong> 如果您在相關時間段內在 Replimune Group, Inc.的股票中遭受損失——即使您仍持有股份——請訪問 https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
<p><strong>為什麼選擇 Levi &amp; Korsinsky：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟中代表投資者方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂尖證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
<p><strong>聯繫方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>紐約，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>電話：(212) 363-7500</p>
<p>傳真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>

REPL

<p>在 Replimune Group, Inc.遭受損失的投資者被敦促在 2025 年 9 月 22 日之前聯繫 Levi & Korsinsky，關於一項指控證券欺詐的集體訴訟，該訴訟涉及的時間為 2024 年 11 月 22 日至 2025 年 7 月 21 日。訴訟聲稱該公司對 IGNYTE 試驗做出了虛假陳述，導致對其商業前景產生誤導性信息。Levi & Korsinsky 是一家知名的證券訴訟事務所，為受影響的股東提供無成本或無義務的幫助</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / August 4, 2025 /</strong> If you suffered a loss on your <strong>Replimune Group, Inc.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p><strong>紐約，紐約 / ACCESS Newswire /2025 年 8 月 4 日/</strong> 如果您在 <strong>Replimune Group, Inc.</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
</div><p>https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Replimune Group, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025.</p>
<div class="lb-trans"><p><strong>訴訟：</strong> 針對 Replimune Group, Inc.提起了一項集體訴訟，旨在為在 2024 年 11 月 22 日至 2025 年 7 月 21 日期間受到證券欺詐影響的股東追回損失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.</p>
<div class="lb-trans"><p><strong>案件詳情：</strong> 提起的投訴指控被告作出了虛假陳述和/或隱瞞了以下事實：(1) 被告在知道或應該知道的重大問題下，魯莽地誇大了 IGNYTE 試驗的前景，導致 FDA 認為 IGNYTE 試驗不充分且控制不佳；(2) 因此，被告關於 Replimune 的業務、運營和前景的陳述在所有相關時間內都是實質性虛假和誤導的，或完全缺乏合理依據。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Replimune Group, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下來會發生什麼？</strong> 如果您在相關時間段內在 Replimune Group, Inc.的股票中遭受損失——即使您仍持有股份——請訪問 https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=159673&amp;wire=1&amp;utm_campaign=5 瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>為什麼選擇 Levi &amp; Korsinsky：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟中代表投資者方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂尖證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>紐約，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>電話：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>傳真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div>

投資者被建議在2025年9月22日之前聯繫 Levi & Korsinsky 以獲取信息 - Replimune 集團公司 (REPL)